NCT04638686View on ClinicalTrials.gov

REal-Life Cohort With DOlutegravir + LAmivudina

CompletedOBSERVATIONAL
Enrollment

185

Participants

Timeline

Start Date

June 15, 2020

Primary Completion Date

June 15, 2021

Study Completion Date

March 31, 2022

Conditions
HIV-1-infection
Interventions
DRUG

Dolutegravir 50 MG

The subjects started their antiretroviral treatment containing dolutegravir once a day.

DRUG

Lamivudine 300 MG

The subjects started their antiretroviral treatment containing lamivudine once a day

Trial Locations (1)

28040

Alfonso Cabello, Madrid

All Listed Sponsors
lead

Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz

OTHER

NCT04638686 - REal-Life Cohort With DOlutegravir + LAmivudina | Biotech Hunter | Biotech Hunter